In regions where broiler and layer welfare protocols prohibit repeated water line interruptions, Yinhuang Injection Veterinary Grade API is converted into water-soluble powder for continuous proportioner medication. The principal production-line constraint is not active marker instability under dry blending but hygroscopic bridging that occurs when the milled chlorogenic-acid-rich extract contacts glucose monohydrate at relative humidity above 60% RH; batch records from horizontal ribbon blenders document lumping at discharge gates and baicalin assay deviation of ±0.4% w/w between top, middle, and bottom sampling points when pre-milling moisture is not controlled below 3.0% loss on drying. The downstream powder is tested against the relevant Chinese Veterinary Pharmacopoeia 2020 monograph for Yinhuang preparations, including dissolution in water, marker content uniformity, and microbial limits; residual solvent control follows VICH GL18 with ethanol and ethyl acetate monitored by headspace GC-FID. Export batches supplied to feed-mill customers are accompanied by a certificate of analysis aligned with feed hygiene sampling under Regulation (EC) No 183/2005 where the product is handled as a veterinary medicinal premix rather than as a zootechnical feed additive. A representative working inclusion window for the final water-soluble powder is 0.05%–0.20% w/w of Yinhuang API on an anhydrous glucose base; when the API batch CoA reports 8.0% w/w baicalin, a 0.10% inclusion supplies 8 mg baicalin per 100 g powder, enabling in-house dose titration at 1–2 g powder per litre of drinking water according to veterinary prescription. The manufacturing sequence on a named equipment line involves air-classified milling of the API through a hammer mill with 0.5 mm screen to a D90 below 150 μm, followed by dry ribbon blending at 12–15 rpm for 20 min with anhydrous glucose and 0.5% w/w colloidal silicon dioxide as flow aid. Finished goods are packed as 100 g, 500 g, and 1 kg foil-lined pouches, and 5 kg HDPE pails for large farms. The API should not be premixed with strongly acidic citric acid granules because chlorogenic acid degrades below pH 3.0 and baicalin solubility drops sharply; separate acidifier dosing is required.

What Limits Sterile Filtration of 5% Yinhuang API in Swine Parenterals?

Sterile filtration of Yinhuang Injection Veterinary Grade API at 5% w/v in water for injection is limited not by bioburden but by the colloidal behaviour of flavonoid aglycones released from baicalin at temperatures above 70°C. Production-scale cartridge filtration on 0.45 μm PVDF followed by 0.22 μm PES achieves a flux of 120–180 L/m²/h only when the bulk solution pH is maintained between 6.5 and 7.2; below pH 5.0, baicalin precipitates as a fine sediment that increases differential pressure across the filter train by 0.8–1.2 bar within 300 L batches. Aseptic filling lines for this dosage form operate under ISO 14644-1 Grade B with Grade A local protection; the finished injection is tested for sterility according to the Chinese Veterinary Pharmacopoeia 2020 sterility test, bacterial endotoxins below 0.50 EU/mg of API, and particulate matter per USP <788>. The parenteral formula uses 5.0% w/v Yinhuang Injection Veterinary Grade API, dissolved with 0.1% w/v sodium metabisulfite as antioxidant, 0.9% w/v sodium chloride for isotonicity, and 0.15% w/v benzyl alcohol for multi-dose vials where national regulations allow. API is dispersed in 80% of the final volume of water for injection at 40°C, adjusted to pH 6.8 with 0.1 M disodium hydrogen phosphate, clarified through 0.45 μm PVDF, then sterilizing filtered through 0.22 μm PES at ≤2.0 bar pressure. The filtered bulk is held under nitrogen in a jacketed stainless-steel vessel at 15–25°C and filled into amber type II vials with nitrogen flushing. Final presentations are 10 mL, 50 mL, and 100 mL amber glass vials with bromobutyl rubber stoppers and aluminium flip-off caps. Terminal autoclaving is not used because thermal exposure above 110°C reduces chlorogenic acid content by more than 5% per cycle; terminal sterilisation is therefore replaced by aseptic filtration due to the heat-labile marker.

Thermal degradation of chlorogenic acid during pellet conditioning is the central downstream issue when Yinhuang Injection Veterinary Grade API is incorporated into calf and lamb feed premixes. In a typical pellet line, the conditioner exposes the API to steam at 70–85°C for 20–40 seconds; marker recovery in compound feed pellets is maintained at 88–94% only when the API is sprayed onto a ground wheat bran carrier, whereas recovery falls below 80% when the API is dry-mixed into the meal before conditioning. Published data for this specific configuration is limited; plant trials should include marker recovery testing per ISO 6497:2002 before finalizing incorporation rates. Premix manufacture follows GMP+ BA2 feed safety assurance and ISO 22000; the HACCP plan includes metal detection, sequence flushing, and mycotoxin control. The API is accompanied by a certificate of analysis reporting heavy metals below 10 mg/kg, arsenic below 2 mg/kg, and microbial limits aligned with ISO 4833-1:2013. Representative incorporation rate is 1.0–2.0 kg Yinhuang API per tonne of complete feed, or 5% w/w in a wheat bran and limestone premix intermediate. The exact rate is adjusted so that daily consumed feed delivers 5–10 mg baicalin per kg body weight in calves and lambs. The premix is produced by first blending the API with precipitated silica at 1% w/w to reduce hygroscopic caking, then adding to a double-ribbon paddle mixer with wheat bran and calcium carbonate carrier at 18 rpm for 15 min. The intermediate is not pelleted; instead it is top-dressed onto pelleted feed or mixed in a vertical screw mixer immediately before feeding. If the complete feed must be pelleted, the API is applied post-pellet in a vacuum coater at 0.8 bar negative pressure to avoid thermal loss. Packaging types include 5 kg, 20 kg multi-wall paper bags with inner polyethylene liner, and 25 kg woven polypropylene bags for bulk farm delivery. The API should not be co-ground with mineral premixes containing high levels of iron or aluminium salts because baicalin chelation can form coloured complexes and reduce free marker availability.

Wet Granulation Parameters for Baicalin-Chlorogenic Acid Soluble Granules

Wet granulation of Yinhuang API for weaned-piglet drinking water requires careful control of binder viscosity and drying dew point because chlorogenic acid is prone to oxidative polymerisation at elevated moisture and alkalinised granulation liquid. The formulation uses 2.0% w/w Yinhuang Injection Veterinary Grade API in a sorbitol-maltodextrin matrix, equivalent to 20 g API per 1 kg granule; dilution in drinking water is 1 g granules per 1 L water. The granulation process on a top-drive high-shear granulator uses impeller speed 300 rpm and chopper speed 1500 rpm for 90 seconds, with 5% w/w polyvinylpyrrolidone K30 binder solution added by peristaltic pump at 0.5 L/min. Drying is conducted in a fluid-bed dryer with inlet air at 65°C until product moisture reaches 2.5–3.5%; final sieving collects the 16–40 mesh fraction. Granules are tested for dissolution, moisture, and marker content uniformity against the relevant Chinese Veterinary Pharmacopoeia 2020 monograph; residual solvents are controlled under VICH GL18. Finished product types include 50 g and 200 g aluminium foil sachets and 1 kg PET/AL/PE pouches. Lactose is excluded from the formulation because Maillard reaction products at drying temperatures can bind chlorogenic acid and reduce assay recovery; maltodextrin is used as the primary carbohydrate carrier instead.

Dispensing of Yinhuang Injection Veterinary Grade API into direct-compression tablets for neonatal calf and lamb fever support requires a binding system tolerant of chlorogenic acid’s acidic phenol groups. The API is not directly compressible; its bulk density is typically 0.35–0.45 g/cm³ and Carr index exceeds 30, so dry granulation is inserted before tablet compression. Direct-compression formula contains 15% w/w Yinhuang API, 70% microcrystalline cellulose, 10% crospovidone, 3% magnesium stearate, and 2% colloidal silica. The 1 g tablet delivers 150 mg API, adjusted to label dose. The API is dry-granulated with half of the microcrystalline cellulose through a roller compactor at roll pressure 40 bar, milled to 1.0 mm, then final-blended with remaining excipients in a bin blender at 10 rpm for 20 min. Compression is performed on a rotary tablet press with 12 mm round tooling at 30–50 N hardness; friability below 1.0% is confirmed by the USP <1216> method. Tablets are manufactured as veterinary preparations under ISO 22000; if sold as registered veterinary medicines, the finished product monograph follows the Chinese Veterinary Pharmacopoeia 2020 tablet criteria for disintegration, weight variation, and dissolution. Cleaning validation follows EU GMP Annex 15 with carry-over limits calculated from toxicological data. Finished goods are 1 g and 2 g tablets, packed in 100-tablet HDPE bottles with desiccant. Capsule filling is preferable to compression if the API content exceeds 25% w/w because die-fill consistency deteriorates; capsules use size 00 gelatin or HPMC shells depending on target market.

When Liquid Proportioner Dilution Demands Chelation Control in Turkey Drinker Lines

When a 5% stock solution of Yinhuang Injection Veterinary Grade API is proportioned into turkey drinker lines at 1:100, the limiting factor is not active assay but the reaction of baicalin with hard-water cations in the dilution manifold. In production-scale field audits, stock solutions prepared with deionised water maintain a clear amber appearance for 72 h, while the same stock diluted with 250 mg/L CaCO₃-equivalent hard water develops visible flocculation within 6 h; the flocculated baicalin-calcium complex blocks nipple drinker orifices and reduces delivered dose. The oral solution concentrate is produced under ISO 14644-1 Class 8, filtered through 5 μm polypropylene to remove particulate, and tested for microbial limits per ISO 4833-1:2013; residual solvents are controlled per VICH GL18. The concentrate contains 5.0% w/v Yinhuang API, 0.2% w/v disodium EDTA as chelation agent, 0.3% w/v potassium sorbate, and 0.1% w/v citric acid to pH 5.5–6.0. In-use dilution is 1:100 to 1:200 in drinking water, producing a final API concentration of 250–500 mg/L. The API is dispersed in purified water at 35°C, pH adjusted with 0.1 M sodium citrate, then circulated through a 5 μm bag filter before filling into opaque high-density polyethylene jerry cans; no terminal heat step is used, and preservation is chemical rather than thermal. Pack types include 1 L, 5 L, and 20 L opaque HDPE jerry cans with tamper-evident caps and dosing chambers. The stock solution must not be combined with oxidising disinfectants such as sodium hypochlorite in the same water line because chlorogenic acid is rapidly oxidised to quinone-like products that deepen colour and reduce marker content.